Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIT101 versus rituximab in first-line low tumor burden follicular lymphoma
2016-001966-27Phase 3Completed
- Sponsor
- Archigen Biotech Limited
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) and B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by Archigen Biotech Limited. Primary endpoint: Primary efficacy endpoint. Started Jul 2016; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2016-001966-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001966-27.